Login
Zimmer Biomet Holdings NYSE: ZBH
| Name | Zimmer Biomet Holdings |
| Ticker | ZBH |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Specialized Medical Devices |
| Price | 163.46 |
| 52W Low/High | 80.63 / 163.46 |
| Market cap | 34 B |
| 1Y Total Return |
9.99%
Average |
| 1Y Volatility |
49.82%
Less Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Details
| Ticker | ZBH |
| Name | Zimmer Biomet Holdings |
| ISIN | US98956P1021 |
| CUSIP | 98956P102 |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Specialized Medical Devices |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | US S&P 500 Index |
Share as of 1/20/21
| Close Price | 163.46 |
| 52W Low/High | 80.63 / 163.46 |
| Market cap | 34 B |
| 1Y Total Return |
9.99%
Average |
| 1Y Volatility |
49.82%
Less Risk |
| Beta | 1.09 |
| PE (trailing) | - |
| 12M Dividends | 0.96 |
| Last Dividend Date | 12/24/20 |
| Dividend Yield | 0.59% |
Fin. Strength
| Net Profit Margin | -2.2% |
| Cash from Op. / Cur. Liabilities | 0.53 |
| Diluted Earnings / Share | -0.76 |
| ROE | - |
| ROIC | 0.1% |
| Price / Revenue | 4.8 |
| Price / Book | 2.9 |
| Price / CF | 28.3 |
| Current Ratio | 2.3 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | 0.70 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
7,065
|
7,928
|
7,930
|
7,733
|
7,604
|
5,287
|
|
| Gross Profit |
5,002
|
5,674
|
5,650
|
5,569
|
5,175
|
3,842
|
|
| R&D |
393
|
429
|
386
|
371
|
356
|
229
|
|
| EBITDA |
1,050
|
1,003
|
1,818
|
2,005
|
1,933
|
946
|
|
| Operating Income |
8
|
10
|
784
|
1,018
|
856
|
480
|
|
| Net Income exc. Extra |
-
|
-
|
1,753
|
652
|
363
|
174
|
|
| per Share | |||||||
| Diluted avg Shares |
209
|
207
|
205
|
204
|
203
|
206
|
|
| EPS exc. Extra |
-0.76
|
-0.48
|
8.58
|
3.19
|
1.82
|
1.00
|
|
| Dividend |
0.96
|
0.96
|
0.96
|
0.96
|
0.94
|
0.88
|
|
| Div. Yield (an.) |
0.71%
|
0.70%
|
0.73%
|
0.82%
|
0.72%
|
0.94%
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
24,026
|
24,315
|
25,382
|
26,418
|
27,037
|
26,689
|
|
| Cash, Eq & Invt ShortTerm |
967
|
513
|
525
|
481
|
489
|
1,810
|
|
| Total Current Assets |
5,153
|
4,402
|
4,513
|
4,433
|
4,698
|
6,395
|
|
| Total Non-Current Assets |
18,873
|
19,914
|
20,869
|
21,984
|
22,338
|
20,294
|
|
| Intangibles |
15,889
|
16,885
|
18,421
|
19,370
|
19,771
|
17,503
|
|
| Total Liabilities |
12,147
|
12,230
|
13,159
|
15,967
|
17,290
|
16,696
|
|
| Total Current Liabilities |
2,266
|
3,774
|
2,391
|
3,010
|
2,312
|
1,787
|
|
| Long Term Debt |
9,881
|
8,456
|
10,768
|
12,957
|
14,978
|
14,909
|
|
| Shareholder equity |
11,872
|
12,082
|
12,217
|
10,450
|
9,746
|
9,992
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
1,203
|
1,542
|
1,771
|
1,807
|
1,468
|
749
|
|
| Depreciation |
1,021
|
1,007
|
1,050
|
1,050
|
1,072
|
521
|
|
| Cash from Investing |
-436
|
-674
|
-462
|
-529
|
-1,476
|
-7,598
|
|
| Capex |
441
|
713
|
446
|
514
|
499
|
330
|
|
| Cash from Financing |
-318
|
-873
|
-1,260
|
-1,287
|
-973
|
7,382
|
|
| Stock Issued |
130
|
130
|
116
|
156
|
-424
|
107
|
|
| Debt (LT) Issued |
-223
|
-803
|
-1,155
|
-1,222
|
-359
|
7,432
|
|
| Free Cash Flow |
-1,677
|
1,653
|
2,221
|
2,528
|
2,030
|
-443
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
22.1%
|
8.4%
|
4.8%
|
3.3%
|
|
| NCFO / Op.Income |
14,490.4%
|
15,117.6%
|
225.8%
|
177.5%
|
171.4%
|
156.1%
|
|
| Current Ratio |
2.3
|
1.2
|
1.9
|
1.5
|
2.0
|
3.6
|
|
| Financial Leverage D/E |
0.70
|
0.69
|
0.75
|
1.00
|
1.19
|
1.19
|
|
| Return on Capital Avg |
0.1%
|
0.0%
|
10.4%
|
4.3%
|
1.2%
|
2.6%
|
|
| Return on Shareholder Equity |
-
|
-
|
15.5%
|
6.5%
|
3.7%
|
2.1%
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available